KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Operating Margin (2017 - 2025)

Historic Operating Margin for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to 89.63%.

  • Aquestive Therapeutics' Operating Margin fell 284100.0% to 89.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 424.07%, marking a year-over-year increase of 4599000.0%. This contributed to the annual value of 3052.68% for FY2024, which is 30228200.0% down from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' Operating Margin is 89.63%, which was down 284100.0% from 113.65% recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Operating Margin ranged from a high of 30.39% in Q4 2024 and a low of 325.85% during Q2 2021
  • Moreover, its 5-year median value for Operating Margin was 77.23% (2022), whereas its average is 87.65%.
  • The largest annual percentage gain for Aquestive Therapeutics' Operating Margin in the last 5 years was 2845600bps (2021), contrasted with its biggest fall of -4048500bps (2021).
  • Quarter analysis of 5 years shows Aquestive Therapeutics' Operating Margin stood at 105.33% in 2021, then rose by 5bps to 100.29% in 2022, then skyrocketed by 70bps to 29.62% in 2023, then surged by 203bps to 30.39% in 2024, then plummeted by -395bps to 89.63% in 2025.
  • Its Operating Margin stands at 89.63% for Q3 2025, versus 113.65% for Q2 2025 and 222.08% for Q1 2025.